Forward Looking Statements

This presentation contains "forward-looking statements" within the meaning of the federal securities laws, including statements concerning the ability of BioRestorative Therapies, Inc. (the “Company”) to develop its adult stem cell business, the future of regenerative medicine and the role of adult stem cells in that future, and the potential revenue growth of the Company’s business. Such forward-looking statements, including revenue assumptions, involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: (1) the Company’s limited operating history, lack of significant revenues, substantial losses since inception, and substantial working capital deficiency and stockholders’ deficiency, (2) the Company’s ability to obtain sufficient financing to satisfy its debt obligations and funds its operations, (3) the ability of the Company to obtain reimbursement for its therapies from private and governmental insurers, (4) the Company’s ability to build management, human resources and infrastructure necessary to support the growth of its business, (5) competitive factors beyond the Company’s control, (6) scientific and medical developments beyond the Company’s control, (7) the Company’s ability to comply with applicable federal, state, local, and international governmental requirements, (8) the Company’s ability to protect its proprietary rights both within and outside the United States, and (9) other factors discussed in the Company’s periodic documents filed with the Securities and Exchange Commission (which are available for review at www.sec.gov). Given these uncertainties, you are cautioned not to place undue reliance on such forward-looking statements. We assume no obligation to update these forward-looking statements to reflect actual results or changes in factors or assumptions affecting such forward-looking statements.
BioRestorative Therapies (BRT)
Research and Development focus cell based therapies

*brtxDISC™* Mesenchymal stem cells for the treatment of chronic Lumbar Disc Disease (cLDD)

Lead therapeutic product – successful pre-IND meeting

*ThermoStem®* Brown adipose tissue preclinical program for the treatment of metabolic disorders

Cell based approach - brown adipose derived stem cells
Pre-clinical therapy for obesity and type 2 diabetes
Potential small molecule application and biologic discovery program

*BRT develops products and medical therapies using cell and tissue protocols, primarily involving adult stem cells*
BRT’s Lead Therapeutic Product: *brtxDISC™*

Addressing the pathophysiology and symptoms of intervertebral disc disease.
**brtxDISC™** Treatment for Lumbar Disc Disease

**brtxDISC™** is BioRestorative Therapies’ lead product candidate

**brtxDISC™** is an autologous hypoxic cultured Mesenchymal Stem Cell (MSC) product derived from adult human bone marrow formulated with a proprietary carrier

13/132,840 Methods and Compositions to Facilitate Repair of Avascular Tissue

Therapeutic application of **brtxDISC™** is a sterile cellular product to be provided in vials for injection into damaged lumbar discs in a 30 minute outpatient procedure
The Market Opportunity: Lower Back Pain (LBP)

LBP is the most common, disabling and costly musculoskeletal problem

Global population prevalence of LBP

84% of populace with an occurrence during lifetime
23% with pain recurrence within 6 months
11% with chronic LBP

Out of 291 medical conditions evaluated in the Global Burden of Disease 2010 Study, LBP ranked as the number one cause of disability

Quality of life deteriorates with lower back pain

Annual direct healthcare costs of LBP in the United States is approaching $100 billion
The Problem: No Good Treatments for Lower Back Pain

Today’s treatments do not address the pathophysiology of the disease

Non-Surgical treatments

Physical therapy and weight loss
Non-steroidal anti-inflammatory drugs
Spinal manipulation (chiropractic care)
Epidural steroid injections

Surgical treatments

Surgery (percutaneous, minimally invasive, fusion/disc replacement)

Clinical and economic outcomes point to the need for a radical change in treatment

At the present time, therapy for discogenic back pain is largely empirical and aimed at relieving symptoms rather than addressing the underlying disease mechanism.
The Solution: *brtxDISC™* to treat Lumbar Disc Disease

The clinical benefit of mesenchymal stem cells (MSCs) is due to a number of mechanisms that act upon the site of pathology in the disc

**Replacement:** MSCs differentiation into chondrocytes

**Repair/Regeneration:** Activation of certain beneficial signal transduction pathways for the recruitment of endogenous cells to the vasculature

**Repair/Regeneration:** Inducement of the immune system to inhibit the chronic inflammation associated with the damaged disc

**Repair/Regeneration:** Restoration of system that removes lactic acid waste from the disc

*Replacement, regeneration and repair of cells promotes healing of the disc*
**brtxDISC™** Treatment Process

**brtxDISC™** production begins with the physician collecting (1) bone marrow and (2) blood plasma from the patient

- Bone marrow harvested from the patient’s iliac crest under a local anesthesia
- Peripheral blood collected from the patient

Physician sends patient bone marrow and blood samples to BioRestorative for lab culturing and proprietary carrier preparation

Process takes approximately 3 weeks

BRT sends therapeutic stem cell cryopreserved in a vial back to physician where it is thawed prior to the procedure

Patient receives cells via a 25 gauge needle device in the physician office in a 30 minute outpatient procedure
Clinical Results from a Physician Sponsored Study

Patients received injection of autologous Mesenchymal Stem Cells to the intervertebral disc

Autologous mesenchymal stems cells are safe
- No adverse events observed
- Maximum dose of 40 million stem cells well tolerated

Mesenchymal stems cells are effective
- Patients experienced pain relief, healing
- Benefits in mobility and decreases in disability
- Beneficial disc morphology changes observed

Study suggests that autologous mesenchymal stem cells administered for lower back pain are safe and effective
Impact of Stem Cells on Disc Morphology

MRIs of patient treated with BioRestorative Stem Cell Technology

*Stem cells may have a significant impact on the morphology of the disc and bring relief of symptoms*
Clinical Development Plans

_brtxDISC™_ is an autologous MSC product injected into the intervertebral disc. MSCs will be formulated with a proprietary carrier.

Therapeutic application of _brtxDISC™_ in treatment of cLDD delivered by a standard 20G 3.5 inch introducer needle and a 25G 6 inch needle to enter the disc

Company envisions conducting Phase 1/2a, Phase 2b, Phase 3 clinical trials under the regulation of the FDA’s Center for Biologics Evaluation and Research (CBER)
  - Phase 1/2a will investigate safety and determine maximum tolerated dose
  - Phase 2b will investigate safety and efficacy of selected dose
  - Phase 3 will further investigate safety and efficacy of selected dose

_BioRestorative Therapies has a deep and rich pipeline of additional regenerative medicine therapies_
brtxDISC™ Clinical Trial Principal Investigators

Gregory E. Lutz, M.D.; BRT Chief Medical Advisor for Spine Medicine

Physiatrist-in-Chief Emeritus for Hospital for Special Surgery (HSS) and is a member of the Board of Trustees

Regenerative Medicine clinical trial experience

Associate Professor of Clinical Rehabilitation Medicine, Weill Medical College of Cornell

Consulting physician to the National Hockey League Players’ Association

Wayne Olan, M.D.; Member of BRT Scientific Advisory Board

Associate Professor at The George Washington University School of Medicine & Health Sciences

Director of Interventional and Endovascular Neurosurgery

Published extensively on minimally invasive spinal interventions

Experience in medical devices for the spine
Target Physicians Likely To Treat Discs with Stem Cells

Large pool of physicians in the United States that will use brtxDISC™

Physicians currently trained and skilled in performing spinal injections are the target physicians for injections of brtxDISC™

- Interventional physiatrists (physical medicine physicians)
- Pain management - anesthesiologists
- Interventional radiologists
- Neurosurgeons

Greater than 10,000 total target physicians estimated in the United States
**brtxDISC™ Revenue Assumptions**

*brtxDISC™* effective in a wide spectrum of lumbar disc disease (from IDD to protrusions to moderate/severe disc degeneration)

Non-steep learning curve for physicians

Up to 10% market penetration in the first year

Maximum market penetration of 80% by year 5

$15,000 price per procedure (acceptable to out-of-pocket early adopters)

- $7,500 of revenue to BioRestorative
- $5,000 of revenue to the physician
- $2,500 of revenue for MRI’s, needles, additional tests, shipping

Compared to cost of surgery that can be as high as $100,000 (disc fusion) without favorable outcomes and significant additional cost and time for physical therapy

Manufacturing cost of *brtxDISC™*~$600 implying a >90% gross margin
### Pipeline Overview and Anticipated Progress in 2015

<table>
<thead>
<tr>
<th>Program</th>
<th>Preclinical</th>
<th>Phase 1</th>
<th>Phase 2</th>
<th>Phase 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous ( \text{brtxDISC}^{\text{TM}} )</td>
<td>Begin Phase 1/2a 2015</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Allogeneic ( \text{brtxDISC}^{\text{TM}} )</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Proprietary Development Project</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Market Adoption Strategy

Phase 3 study showing a clinically meaningful effect of MSCs treating disc protrusions will help drive market adoption

- Long term follow-up data confirming the safety and efficacy of the therapy
- Company plans to conduct other supportive studies
- Promotional activities at spine/orthopedic physician conferences
- Physician education materials and marketing via a sales force
- Economic incentives to the caregiver
- Insurance reimbursement strategy based on clinical and economic data

*Positive Phase 3 results could make brtxDISC™ an accepted standard of care for chronic lower back pain*
Strategic Partnerships for Distribution

Strategic partner will be sought for the marketing and distribution of *brtxDISC™*

Partner characteristics include

- Sales force with presence in the spine/orthopedic care setting
- Expertise and vision for the growth of the regenerative medicine market

BioRestorative product pipeline presents an attractive fit for companies with presence in the spine/orthopedic and regenerative medicine markets

Ample partnership opportunities exist for all global markets

*North America*  *Europe*  *Japan*  *Rest of world*
ThermoStem® Program (Brown Fat Stem Cells)

Potential Treatments for Metabolic Diseases

Magnification of brown adipose derived stem cells cultured and differentiated into brown adipocytes on porous extracellular matrix scaffolds
Metabolic Platform Program

- Obesity
- Metabolic Syndrome
  - Hypertension
  - Myopathies
  - Diabetes
  - Insulin Resistance
  - Atherosclerosis
  - Dyslipidaemia
ThermoStem® Brown Fat Program

“One of the most powerful organs in the body….Since it consumes both glucose and fatty acids, it is possible we could utilize brown fat to treat obesity and metabolic dysfunction seen in diabetes and hyperlipidemia.”

Aaron M. Cypress, M.D., Ph.D., Joslin Diabetes Center and Harvard Medical School

Infants have a larger population of brown fat that is responsible for generating body heat and creating metabolic homeostasis

Potential Cellular Product as allogeneic “off the shelf” product using brown fat stem cells to treat type 2 diabetes and obesity

Developing a novel cellular therapy that transplants brown fat stem cells

BRT has identified a stem cell populations isolated from brown adipose depots in humans
BRT February 2014 Publication in STEM CELLS Journal

Inside This Issue

337 An Osteopontin-Integrin Interaction Plays a Critical Role in Directing Adipogenesis and Osteogenesis by Mesenchymal Stem Cells
Qing Chen, Peishun Shou, Liying Zhang et al.

349 Stimulation of Somatic Cell Reprogramming by ERas-Akt-FoxO1 Signaling Axis
Yong Yu, Dan Liang, Qing Tian et al.

424 Autophagy Regulates Homoeostasis of Pluripotency-Associated Proteins in hESCs
Yun-Hee Cho, Kyu-Min Han, Dongkyu Kim et al.

447 MMP-10 Is Required for Efficient Muscle Regeneration in Mouse Models of Injury and Muscular Dystrophy
Miriam Bobadilla, Natalia Sáinz, José Antonio Rodríguez et al.

500 Transplants of Adult Mesenchymal and Neural Stem Cells Provide Neuroprotection and Behavioral Sparing in a Transgenic Rat Model of Huntington's Disease
Julien Rougnaud, Kyle Fink, Kendra Davis et al.

572 Metabolically Active Human Brown Adipose Tissue Derived Stem Cells
Francisco J Silva, Dolly J Holt, Vanessa Vargas et al.

594 Brief Report: Astrogliosis Promotes Functional Recovery of Completely Transected Spinal Cord Following Transplantation of hESC-Derived Oligodendrocyte and Motoneuron Progenitors
Dunja Lukovic, Lourdes Valdés-Sanchez, Irene Sanchez-Vera et al.

See Complete Table of Contents Inside
BioRestorative Therapies/Pfizer Collaboration

Jointly conducting a study entitled “Development and Validation of a Human Brown Adipose Cell Model”

BRT has a collection of human brown adipose tissue samples, pre-adipocyte cell lines and immortalized cell lines

Characterization of identity and metabolic function of cell lines
Preclinical Study Results on Glucose and Body Weight

(A) Glucose levels of mice transplanted with BADSC/scaffolds and controls; (B) Weights of mice transplanted with BADSC/scaffolds and controls.
Preclinical Study Results on Triglyceride and Cholesterol Levels

<table>
<thead>
<tr>
<th></th>
<th>Baseline</th>
<th>1Mth</th>
<th>2Mth</th>
<th>3Mth</th>
<th>4Mth</th>
</tr>
</thead>
<tbody>
<tr>
<td>Trig – ctrl mg/dL</td>
<td>115±16</td>
<td>147±13</td>
<td>159±21</td>
<td>165±14</td>
<td>188±16</td>
</tr>
<tr>
<td>Trig – tx mg/dL</td>
<td>120±14</td>
<td>142±15</td>
<td>131±19</td>
<td>113±11</td>
<td>114±10</td>
</tr>
<tr>
<td>Chol – ctrl mg/dL</td>
<td>136±16</td>
<td>151±15</td>
<td>188±26</td>
<td>224±34</td>
<td>251±22</td>
</tr>
<tr>
<td>Chol – tx mg/dL</td>
<td>125±12</td>
<td>130±14</td>
<td>136±24</td>
<td>126±19</td>
<td>130±15</td>
</tr>
</tbody>
</table>
# BioRestorative Therapies Pipeline Summary

## Intervertebral Disc Therapeutic Program

<table>
<thead>
<tr>
<th>Product ID</th>
<th>Candidate Design</th>
<th>Preclinical Studies</th>
<th>Product Characterization</th>
<th>Human Clinical Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>brtxDISC™ Autologous</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>brtxDISC™ Allogeneic</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

## Brown Fat Therapeutic Program

<table>
<thead>
<tr>
<th>Product ID</th>
<th>Candidate Design</th>
<th>Preclinical Studies</th>
<th>Product Characterization</th>
<th>Human Clinical Studies</th>
</tr>
</thead>
<tbody>
<tr>
<td>ThermoStem®</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other Candidates</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
In Summary

*brtxDISC™*

Successful pre-IND meeting with FDA
Expect to commence clinical trial by year end

*ThermoStem®*

Maintenance and regulation of metabolism

Metabolic Platform (Brown Fat) Program addresses large markets

Pfizer collaboration

*Deep expertise in stem cell biology and public management*
Thank You

OTCBB: BRTX